Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.54), $0.16 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $120.6 million versus the consensus estimate of $118.82 million.

2020 Financial Guidance:

• Acadia reiterates its NUPLAZID net sales guidance of $430 to $450 million.
• GAAP R&D guidance is increased to $325 to $340 million from the previous range of $265 to $280 million, primarily as a result of the $52.8 million upfront and transaction expenses associated with the acquisition of CerSci Therapeutics.
• GAAP SG&A guidance is decreased to $385 to $400 million from the previous range of $400 to $420 million.
• Non-cash stock-based compensation expense guidance is decreased to $80 to $90 million from the previous range of $90 to $100 million.
• 2020 year-end cash, cash equivalents, and investment securities guidance of $570 to $590 million is unchanged.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.